Logistic analysis of the association between RAC1 expression and DLBCL clinical features showed that high-level expression of RAC1 was significantly associated with clinical stages (III/IV vs. I/II: Odds Ratio [OR] = 0.234, 95% CI = 0.058–0.844, p = 0.032) (Table 2). The gene discussed is RAC1; the disease is diffuse large B-cell lymphoma.